Cellular therapies in no-option critical limb ischemia: present status and future directions

Area of Science:

• Vascular Biology
• Regenerative Medicine
• Cellular Therapeutics

Background:

• Critical limb ischemia (CLI) is an advanced stage of lower extremity arterial disease causing significant disability and amputations.
• No-option CLI (N-O CLI) patients lack feasible revascularization options, necessitating novel treatments.
• Cellular therapies have emerged as a potential strategy for vascular repair and regeneration in N-O CLI.

Purpose of the Study:

• To review the current status and future directions of cellular therapies for N-O CLI.
• To highlight advances in cell sources, therapeutic mechanisms, and alternative cell-free approaches.
• To address limitations of previous studies and guide future research in N-O CLI treatment.

Main Methods:

• Review of pre-clinical and clinical studies on cellular therapies for N-O CLI.
• Analysis of proposed mechanisms for vascular reparation and regeneration.
• Evaluation of recent advances, including standardized cell sources and cell-free preparations.

Main Results:

• Early trials suggested clinical benefits, but meta-analyses of randomized controlled trials remain inconclusive.
• Limitations include poorly defined cell populations, small sample sizes, and short follow-up periods.
• Recent progress involves standardized cell sources, better mechanistic understanding, and development of cell-free and engineered cell therapies.

Conclusions:

• Standardized cell sources and improved understanding of mechanisms offer new hope for N-O CLI.
• Cell-free preparations and advanced therapy medical products are promising future directions.
• Further rigorous clinical trials are needed to establish the efficacy of these novel therapies for N-O CLI.